Data from: Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T-cadherin
Data files
Apr 09, 2024 version files 47.37 MB
-
Image_Data.zip
47.33 MB
-
README.md
36.06 KB
Abstract
Pharmacological activation of hypoxia-inducible factor 1alpha (HIF-1α), a hypoxia-responsive transcription factor, has attracted increasing attention due to its efficacy not only in renal anemia but also in various disease models. Our study demonstrated that a HIF-1 activator enhanced exosome production from cultured endothelial cells synergistically with adiponectin, an adipocyte-derived factor, through both transcriptional induction and posttranscriptional stabilization of an adiponectin binding partner, T-cadherin. Increased exosome levels were observed in wild-type mice but not in T-cadherin null mice after consecutive administration of roxadustat. Adiponectin- and T-cadherin-dependent increased exosome production may be involved in the pleiotropic effects of HIF-1 activators.
README: Data from: Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T-cadherin
https://doi.org/10.5061/dryad.c866t1gdq
This README file was generated on 2024-04-09 by Kohei Fujii.
GENERAL INFORMATION
Title of Dataset:
Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T cadherinAuthor Information
A. Corresponding author Contact Information
Name: Yuya Fujishima M.D., Ph.D. and Shunbun Kita, Ph.D.
Institution: Osaka University
Address: 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan
Email: y.fujishima@endmet.med.osaka-u.ac.jp.Date of data collection (single date, range, approximate date): 2017-2023
Geographic location of data collection: Japan
Information about funding sources that supported the collection of the data: This work was supported in part by Grants-in-Aid for Scientific Research (C) no. 21K16353 (to Y.F.), no. 22K08669 (to S.K.), no. 21K16340 (to S.F.), no. 23K07989 (to N.M.), and no. 23K08006 (to H.N.) Japan Association of Medical Research and Development no. 22712587 (to S.K. and I.S.), MSD Life Science Foundation (to S.F.), Bayer Scholarship for Cardiovascular Research (to Y.F.), Manpei Suzuki Diabetes Foundation (to Y.F.), and Suzuken Memorial Foundation (to Y.F.). The funding agencies had no role in the study design, data collection, analysis, decision to publish, or manuscript preparation.
SHARING/ACCESS INFORMATION
Licenses/restrictions placed on the data: Attribution 4.0 International License (CC BY 4.0)
Links to publications that cite or use the data: Kohei Fujii, Yuya Fujishima, Shunbun Kita, Keitaro Kawada, Keita Fukuoka, Taka-aki Sakaue, Tomonori Okita, Emi Kawada-Horitani, Hirofumi Nagao, Shiro Fukuda, Norikazu Maeda, Hitoshi Nishizawa, and Iichiro Shimomura (2024). Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T cadherin.
Links to other publicly accessible locations of the data: None
Links/relationships to ancillary data sets: None
Was data derived from another source? No
A. If yes, list source(s): NARecommended citation for this dataset: Kohei Fujii, Yuya Fujishima, Shunbun Kita, Keitaro Kawada, Keita Fukuoka, Taka-aki Sakaue, Tomonori Okita, Emi Kawada-Horitani, Hirofumi Nagao, Shiro Fukuda, Norikazu Maeda, Hitoshi Nishizawa, and Iichiro Shimomura (2024). Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T cadherin. Dryad Digital Repository. https://doi.org/10.5061/dryad.c866t1gdq
Description of the data and file structure
Data & File flowview
- File List:
In Image Lab Image Document Folder
A) User 2023-03-24 14h44m45s.scn
B) User 2023-03-24 14h50m06s.scn
C) User 2023-03-24 14h53m14s.scn
D) User 2023-03-14 13h16m41s.scn
E) User 2023-03-14 13h22m16s.scn
F) User 2023-03-14 13h24m53s.scn
G) User 2022-02-09 17h31m06s.scn
H) User 2022-02-09 17h35m49s.scn
I) User 2022-02-09 17h39m26s.scn
J) User 2023-06-01 14h02m21s.scn
K) User 2023-06-01 14h05m20s.scn
L) User 2023-06-01 14h08m22s.scn
M) User 2023-07-06 13h58m50s.scn
N) User 2023-07-06 14h11m48s.scn
O) User 2023-07-06 14h14m54s.scn
P) User 2023-07-15 13h27m46s.scn
Q) User 2023-07-15 13h31m19s.scn
R) User 2023-07-15 13h35m19s.scn
S) User 2022-11-24 16h38m04s.scn
T) User 2022-11-24 16h43m15s.scn
U) User 2022-11-24 16h48m35s.scn
V) User 2023-10-12 14h02m05s.scn
W) User 2023-10-13 13h40m01s.scn
X) User 2023-07-20 13h35m17s.scn
Y) User 2023-07-20 13h38m46s.scn
Z) User 2023-08-11 13h35m27s.scn
AA) User 2023-08-11 13h39m01s.scn
AB) User 2023-08-11 13h42m07s.scn
AC) User 2023-08-24 11h31m18s.scn
AD) User 2023-08-24 15h28m13s.scn
AE) User 2023-03-22 13h39m35s.scn
AF) User 2023-03-22 13h43m40s.scn
AG) User 2023-06-09 15h35m45s.scn
AH) User 2023-06-09 15h39m49s.scn
AI) User 2023-05-26 16h04m39s.scn
AJ) User 2023-05-26 16h09m52s.scn
AK) F2_T-cad_2017-07-07 11h53m37s 11.477s.scn
AL) F2_Tub_2017-07-07 11h51m34s 13.609s.scnIn TIFF Folder
AM) 1E atubulin.tif
AN) 1E GAPDH.tif
AO) 1E T-cad.tif
AP) 1F atubulin.tif
AQ) 1F GAPDH.tif
AR) 1F T-cad.tif
AS) 2A APN.tif
AT) 2A atubulin.tif
AU) 2A T-cad.tif
AV) 2B Alix.tif
AW) 2B Syntenin.tif
AX) 2B TSG101.tif
AY) 2C APN.tif
AZ) 2C atubulin.tif
BA) 2C T-cad.tif
BB) 2D Alix.tif
BC) 2D Syntenin.tif
BD) 2D TSG101.tif
BE) 3B APN.tif
BF) 3B atubulin.tif
BG) 3B T-cad.tif
BH) 3D SYPRO Ruby.tif
BI) 3D T-cad.tif
BJ) 4G atubulin.tif
BK) 4G T-cad.tif
BL) 4H Alix.tif
BM) 4H Syntenin.tif
BN) 4H TSG101.tif
BO) S1E atubulin.tif
BP) S1E T-cad.tif
BQ) S1H atubulin.tif
BR) S1H T-cad.tif
BS) S2B atubulin.tif
BT) S2B T-cad.tif
BU) S2C atubulin.tif
BV) S2C T-cad.tif
BW) S2D atubulin.tif
BX) S2D T-cad.tif
Relationship between files, if important:
.tif files were made from .scn files by using Image Lab software ver. 6.0.1 (Bio-Lad).
AM) was made from B), AN) from C), AO) from A), AP) from E), AQ) from F), AR) from D), AS) from I), AT) from H), AU) from G), AV) from J), AW) from L), AX) from K), AY) from O), AZ) from N), BA) from M), BB) from P), BC) from R), BD) from Q), BE) from U), BF) from T), BG) from S), BH) from W), BI) from V), BJ) from Y), BK) from X), BL) from Z), BM) from AB), BN) from AA), BO) from AD), BP) from AC), BQ) from AF), BR) from AE), BS) from AH), BT) from AG), BU) from AJ), BV) from AI), BW) from AL) and BX) from AK).Additional related data collected that was not included in the current data package: None
Are there multiple versions of the dataset? No
A. If yes, name of file(s) that was updated: NA
i. Why was the file updated? NA
ii. When was the file updated? NA
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-03-24 14h44m45s.scn and 1E T-cad.tif
Western blot analysis of total cell lysates. UV-F2 cells were treated with roxadustat (Roxa) for 48hrs. Goat polyclonal anti-T-cadherin (Anti-T-cad: AF3264, R&D Systems) was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 50 μM, 4th, 8th, 12th lanes: Roxa 250 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-03-24 14h50m06s.scn and 1E atubulin.tif
Western blot analysis of total cell lysates. UV-F2 cells were treated with roxadustat (Roxa) for 48hrs. Rabbit monoclonal anti-α-tubulin (Anti-α-tubulin: 2125S, Cell Signaling Technology) was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 50 μM, 4th, 8th, 12th lanes: Roxa 250 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-03-24 14h53m14s.scn and 1E GAPDH.tif
Western blot analysis of total cell lysates. UV-F2 cells were treated with roxadustat (Roxa) for 48hrs. Rabbit monoclonal anti- GAPDH (Anti-GAPDH: 2118S, Cell Signaling Technology) was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 50 μM, 4th, 8th, 12th lanes: Roxa 250 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-03-14 13h16m41s.scn and 1F T-cad.tif
Western blot analysis of total cell lysates. UV-F2 cells were treated with daprodustat (Dapro) for 48hrs. Anti-T-cad was used as primary antibody.
Number of variables: 2
Number of cases/rows: 6
Variable List:
- treatment: 1st, 3rd, 5th lanes from the left: control (without Dapro), 2nd, 4th, 6th lanes: Dapro 100 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-03-14 13h22m16s.scn and 1F atubulin.tif
Western blot analysis of total cell lysates. UV-F2 cells were treated with daprodustat (Dapro) for 48hrs. Anti-α-tubulin was used as primary antibody.
Number of variables: 2
Number of cases/rows: 6
Variable List:
- treatment: 1st, 3rd, 5th lanes from the left: control (without Dapro), 2nd, 4th, 6th lanes: Dapro 100 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-03-14 13h24m53s.scn and 1F GAPDH.tif
Western blot analysis of total cell lysates. UV-F2 cells were treated with daprodustat (Dapro) for 48hrs. Anti-GAPDH was used as primary antibody.
Number of variables: 2
Number of cases/rows: 6
Variable List:
- treatment: 1st, 3rd, 5th lanes from the left: control (without Dapro), 2nd, 4th, 6th lanes: Dapro 100 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2022-02-09 17h31m06s.scn and 2A T-cad.tif
Western blot analysis of total cell lysates. UV-F2 cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without high molecular weight adiponectin (HMW-APN) (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2022-02-09 17h35m49s.scn and 2A atubulin.tif
Western blot analysis of total cell lysates. UV-F2 cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without high molecular weight adiponectin (HMW-APN) (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2022-02-09 17h39m26s.scn and 2A APN.tif
Western blot analysis of total cell lysates. UV-F2 cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without high molecular weight adiponectin (HMW-APN) (10 μg/mL) and Roxa (50 μM) for 48 hrs. Goat polyclonal anti-adiponectin (Anti-APN: AF1119, R&D Systems) was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-06-01 14h02m21s.scn and 2B Alix.tif
Western blot analysis of extracellular vechicles (EVs) isolated from cell culture medium by differential ultracentrifugation. UV-F2 cells cultured in FBS-free Advanced DMEM were treated with or without HMW-APN (20 μg/mL) and Roxa (50 μM) for 48 hrs. Rabbit monoclonal anti-ALIX (Anti-Alix: ab186429, abcam) was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 20 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-06-01 14h05m20s.scn and 2B TSG101.tif
Western blot analysis of extracellular vechicles (EVs) isolated from cell culture medium by differential ultracentrifugation. UV-F2 cells cultured in FBS-free Advanced DMEM were treated with or without HMW-APN (20 μg/mL) and Roxa (50 μM) for 48 hrs. Rabbit monoclonal anti-TSG101 (Anti-TSG101: ab125011, Abcam) was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 20 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-06-01 14h05m20s.scn and 2B TSG101.tif
Western blot analysis of extracellular vechicles (EVs) isolated from cell culture medium by differential ultracentrifugation. UV-F2 cells cultured in FBS-free Advanced DMEM were treated with or without HMW-APN (20 μg/mL) and Roxa (50 μM) for 48 hrs. Rabbit polyclonal anti-syntenin (Anti-Syntenin: ab19903, Abcam) was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 20 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-07-06 13h58m50s.scn and 2C T-cad.tif
Western blot analysis of total cell lysates. UV-F2 cells transfected control (Cont) or T-cadherin (T-cad) siRNA were cultured in DMEM containing 5% serum from adiponectin knockout mice with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-07-06 14h11m48s.scn and 2C atubulin.tif
Western blot analysis of total cell lysates. UV-F2 cells transfected control (Cont) or T-cadherin (T-cad) siRNA were cultured in DMEM containing 5% serum from adiponectin knockout mice with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-07-06 14h14m54s.scn and 2C APN.tif
Western blot analysis of total cell lysates. UV-F2 cells transfected control (Cont) or T-cadherin (T-cad) siRNA were cultured in DMEM containing 5% serum from adiponectin knockout mice with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-APN was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-07-15 13h27m46s.scn and 2D Alix.tif
Western blot analysis of EVs isolated from cell culture medium. UV-F2 cells transfected Cont or T-cad siRNA were cultured in FBS-free Advanced DMEM with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-Alix was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-07-15 13h31m19s.scn and 2D TSG101.tif
Western blot analysis of EVs isolated from cell culture medium. UV-F2 cells transfected Cont or T-cad siRNA were cultured in FBS-free Advanced DMEM with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-TSG101 was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-07-15 13h35m19s.scn and 2D Syntenin.tif
Western blot analysis of EVs isolated from cell culture medium. UV-F2 cells transfected Cont or T-cad siRNA were cultured in FBS-free Advanced DMEM with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-Syntenin was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2022-11-24 16h38m04s.scn and 3B T-cad.tif
Western blot analysis of total cell lysates. F2T cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without HMW-APN (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2022-11-24 16h43m15s.scn and 3B atubulin.tif
Western blot analysis of total cell lysates. F2T cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without HMW-APN (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2022-11-24 16h48m35s.scn and 3B APN.tif
Western blot analysis of total cell lysates. F2T cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without HMW-APN (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-10-13 13h40m01s.scn and 3D SYPRO Ruby.tif
SYPRO Ruby staining in the cell lysates of F2T cells immunoprecipitated with Streptavidin SepharoseTM beads at 0, 0.5, 1, 2, and 4 hrs after biotinylation. UV-F2 cells were biotinylated after treated with or without Roxa for 40hrs.
Number of variables: 10
Number of cases/rows: 10
Variable List:
- treatment: 1st lane from the left: at 0hr after biotinylation without Roxa, 2nd lane: at 0.5hr after biotinylation without Roxa, 3rd lane: at 1hr after biotinylation without Roxa, 4th lane: at 2hrs after biotinylation without Roxa, 5th lane: at 4hrs after biotinylation without Roxa, 6th lane: at 0hr after biotinylation with Roxa, 7th lane: at 0.5hr after biotinylation with Roxa, 8th lane: at 1hr after biotinylation with Roxa, 9th lane: at 2hrs after biotinylation with Roxa, 10th lane: at 4hrs after biotinylation with Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-10-12 14h02m05s.scn and 3D T-cad.tif
Western blot analysis of cell lysates of UV-F2 cells immunoprecipitated with Streptavidin SepharoseTM beads at 0, 0.5, 1, 2, and 4 hrs after biotinylation. Anti-T-cad was used as primary antibody.
Number of variables: 10
Number of cases/rows: 10
Variable List:
- treatment: 1st lane from the left: at 0hr after biotinylation without Roxa, 2nd lane: at 0.5hr after biotinylation without Roxa, 3rd lane: at 1hr after biotinylation without Roxa, 4th lane: at 2hrs after biotinylation without Roxa, 5th lane: at 4hrs after biotinylation without Roxa, 6th lane: at 0hr after biotinylation with Roxa, 7th lane: at 0.5hr after biotinylation with Roxa, 8th lane: at 1hr after biotinylation with Roxa, 9th lane: at 2hrs after biotinylation with Roxa, 10th lane: at 4hrs after biotinylation with Roxa.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-07-20 13h35m17s.scn and 4G T-cad.tif
Western blot analysis of total cell lysates. UV-F2 cells transfected Cont or Adam12 siRNA were treated with or without Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-07-20 13h38m46s.scn and 4G atubulin.tif
Western blot analysis of total cell lysates. UV-F2 cells transfected Cont or Adam12 siRNA were treated with or without Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-08-11 13h35m27s.scn and 4H Alix.tif
Western blot analysis of EVs isolated from cell culture medium by differential ultracentrifugation. In the presence of HMW-APN (20 μg/mL), UV-F2 cells transfected control or Adam12 siRNA were cultured in FBS-free Advanced DMEM with or without Roxa (50 μM) for 48 hrs. Anti-Alix was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-08-11 13h39m01s.scn and 4H TSG101.tif
Western blot analysis of EVs isolated from cell culture medium by differential ultracentrifugation. In the presence of HMW-APN (20 μg/mL), UV-F2 cells transfected control or Adam12 siRNA were cultured in FBS-free Advanced DMEM with or without Roxa (50 μM) for 48 hrs. Anti-TSG101 was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-08-11 13h42m07s.scn and 4H Syntenin.tif
Western blot analysis of EVs isolated from cell culture medium by differential ultracentrifugation. In the presence of HMW-APN (20 μg/mL), UV-F2 cells transfected control or Adam12 siRNA were cultured in FBS-free Advanced DMEM with or without Roxa (50 μM) for 48 hrs. Anti-Syntenin was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-08-24 11h31m18s.scn and S1E T-cad.tif
Western blot analysis of total cell lysates. HUVECs were treated with Roxa for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 100 μM, 4th, 8th, 12th lanes: Roxa 200 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-08-24 15h28m13s.scn and S1E atubulin.tif
Western blot analysis of total cell lysates. HUVECs were treated with Roxa for 48 hrs. Anti-α-tubulin was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 100 μM, 4th, 8th, 12th lanes: Roxa 200 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-03-22 13h39m35s.scn and S1H T-cad.tif
Western blot analysis of total cell lysates of UV-F2 cells cultured under 21% or 5% oxygen for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 2
Number of cases/rows: 6
Variable List:
- treatment: 1st, 3rd, 5th lanes from the left: under 21% oxygen, 2nd, 4th, 6th lanes: under 5% oxygen.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-03-22 13h43m40s.scn and S1H atubulin.tif
Western blot analysis of total cell lysates of UV-F2 cells cultured under 21% or 5% oxygen for 48 hrs. Anti-α-tubulin was used as primary antibody.
Number of variables: 2
Number of cases/rows: 6
Variable List:
- treatment: 1st, 3rd, 5th lanes from the left: under 21% oxygen, 2nd, 4th, 6th lanes: under 5% oxygen.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-06-09 15h35m45s.scn and S2B T-cad.tif
Western blot analysis of total cell lysates. UV-F2 cells and those stably overexpressing syndecan-4 (sdc4) were treated with or without Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Control (without Roxa), 2nd, 6th, 10th lanes: with Roxa 50 μM, 3rd, 7th, 11th lanes: overexpressing sdc4, 4th, 8th, 12th lanes: overexpressing sdc4 with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-06-09 15h39m49s.scn and S2B atubulin.tif
Western blot analysis of total cell lysates. UV-F2 cells and those stably overexpressing syndecan-4 (sdc4) were treated with or without Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Control (without Roxa), 2nd, 6th, 10th lanes: with Roxa 50 μM, 3rd, 7th, 11th lanes: overexpressing sdc4, 4th, 8th, 12th lanes: overexpressing sdc4 with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-05-26 16h04m39s.scn and S2C T-cad.tif
Western blot analysis of total cell lysates. UV-F2 cells transfected Cont or Sdc4 siRNA were treated with or without Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: sdc4 siRNA, 4th, 8th, 12th lanes: sdc4 siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: User 2023-05-26 16h09m52s.scn and S2C atubulin.tif
Western blot analysis of total cell lysates. UV-F2 cells transfected Cont or Sdc4 siRNA were treated with or without Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: sdc4 siRNA, 4th, 8th, 12th lanes: sdc4 siRNA with Roxa 50 μM.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: F2_T-cad_2017-07-07 11h53m37s 11.477s.scn and S2D T-cad.tif
Western blot analysis of total cell lysates of UV-F2 cells transfected control or Adam 12, 9, 10, 15, 17, or 19 siRNA. Anti-T-cad was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st-3rd lanes from the left: Control siRNA, 4th-6th lanes: Adam12 siRNA, 7th-9th lanes: Adam9 siRNA, 10th-12th lanes: Adam10 siRNA, 13th-15th lanes: Adam15 siRNA, 16th-18th lanes: Adam17 siRNA, 19th-21st lanes: Adam19 siRNA.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
DATA-SPECIFIC INFORMATION FOR: F2_Tub_2017-07-07 11h51m34s 13.609s.scn and S2D atubulin.tif
Western blot analysis of total cell lysates of UV-F2 cells transfected control or Adam 12, 9, 10, 15, 17, or 19 siRNA. Anti-α-tubulin was used as primary antibody.
Number of variables: 4
Number of cases/rows: 12
Variable List:
- treatment: 1st-3rd lanes from the left: Control siRNA, 4th-6th lanes: Adam12 siRNA, 7th-9th lanes: Adam9 siRNA, 10th-12th lanes: Adam10 siRNA, 13th-15th lanes: Adam15 siRNA, 16th-18th lanes: Adam17 siRNA, 19th-21st lanes: Adam19 siRNA.
Missing data codes: None
Specialized formats or other abbreviations used: None
#########################################################################
Folder names of .scn (e.g. 1E) and file names of .tif (e.g. 1E atubulin) correspond to the figure number or supplementary figure number in paper, respectively.
Sharing/Access information
This is a section for linking to other ways to access the data, and for linking to sources the data is derived from, if any.
Links to other publicly accessible locations of the data: None
Data was derived from the following sources: None
Code/Software
The software used to run this submission is described above.